PDCD1 and melanoma: A trial that evaluated the efficacy of TLR9 agonist SD-101 combined with the PD-1 antibody pembrolizumab for the treatment of patients with advanced melanoma reported an overall ORR of 78%, estimated 12-month PFS of 88%, OS of 89%, and tolerability of a good level (83).